← All trials
NCT05997576
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Apr 30, 2025
- First posted
- Aug 18, 2023
- Last posted
- Aug 21, 2023
- Enrollment
- 675
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.